Amgen Inc. (NASDAQ:AMGN) Stock Holdings Boosted by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC grew its stake in Amgen Inc. (NASDAQ:AMGN) by 1.3% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 231,172 shares of the medical research company’s stock after purchasing an additional 2,977 shares during the period. Amgen accounts for 2.5% of Daymark Wealth Partners LLC’s portfolio, making the stock its 6th biggest position. Daymark Wealth Partners LLC’s holdings in Amgen were worth $74,486,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of AMGN. Saxon Interests Inc. boosted its position in shares of Amgen by 3.0% in the 3rd quarter. Saxon Interests Inc. now owns 1,991 shares of the medical research company’s stock valued at $642,000 after purchasing an additional 58 shares during the period. Peddock Capital Advisors LLC grew its position in shares of Amgen by 11.9% during the third quarter. Peddock Capital Advisors LLC now owns 820 shares of the medical research company’s stock worth $264,000 after acquiring an additional 87 shares during the last quarter. Tilia Fiduciary Partners Inc. grew its position in shares of Amgen by 3.2% during the third quarter. Tilia Fiduciary Partners Inc. now owns 1,244 shares of the medical research company’s stock worth $401,000 after acquiring an additional 39 shares during the last quarter. Howard Financial Services LTD. increased its holdings in shares of Amgen by 7.9% in the 3rd quarter. Howard Financial Services LTD. now owns 2,098 shares of the medical research company’s stock valued at $676,000 after acquiring an additional 153 shares during the period. Finally, True North Advisors LLC raised its stake in Amgen by 24.2% during the 3rd quarter. True North Advisors LLC now owns 1,130 shares of the medical research company’s stock valued at $364,000 after acquiring an additional 220 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. TD Cowen lifted their price objective on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Barclays lifted their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $326.30.

Amgen Trading Up 0.4 %

Shares of NASDAQ AMGN traded up $1.31 during trading on Wednesday, hitting $318.99. 244,389 shares of the company traded hands, compared to its average volume of 2,471,661. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The firm has a market capitalization of $171.12 billion, a P/E ratio of 45.38, a P/E/G ratio of 2.98 and a beta of 0.61. The company has a 50-day moving average price of $326.66 and a 200-day moving average price of $310.06. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. During the same quarter in the previous year, the firm posted $5.00 EPS. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. On average, equities analysts predict that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.82%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.